nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100A13—Cyclophosphamide—Mechlorethamine—lymphatic system cancer	0.0773	0.71	CbGdCrCtD
Olopatadine—Hyperaemia—Carmustine—lymphatic system cancer	0.0355	0.0399	CcSEcCtD
Olopatadine—Ocular discomfort—Methotrexate—lymphatic system cancer	0.0219	0.0246	CcSEcCtD
Olopatadine—S100A13—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.0162	0.149	CbGdCrCtD
Olopatadine—S100A13—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.0153	0.141	CbGdCrCtD
Olopatadine—Depression—Mechlorethamine—lymphatic system cancer	0.0144	0.0162	CcSEcCtD
Olopatadine—Ulcer—Bleomycin—lymphatic system cancer	0.013	0.0146	CcSEcCtD
Olopatadine—Visual disturbance—Fludarabine—lymphatic system cancer	0.0128	0.0144	CcSEcCtD
Olopatadine—Ulcer—Mitoxantrone—lymphatic system cancer	0.0105	0.0118	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00977	0.011	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00956	0.0107	CcSEcCtD
Olopatadine—Infection—Mechlorethamine—lymphatic system cancer	0.00917	0.0103	CcSEcCtD
Olopatadine—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00911	0.0102	CcSEcCtD
Olopatadine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00896	0.0101	CcSEcCtD
Olopatadine—Epistaxis—Fludarabine—lymphatic system cancer	0.00884	0.00992	CcSEcCtD
Olopatadine—Sinusitis—Fludarabine—lymphatic system cancer	0.0088	0.00987	CcSEcCtD
Olopatadine—Eye pain—Carmustine—lymphatic system cancer	0.00862	0.00968	CcSEcCtD
Olopatadine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00837	0.0094	CcSEcCtD
Olopatadine—Pharyngitis—Fludarabine—lymphatic system cancer	0.00835	0.00937	CcSEcCtD
Olopatadine—Visual impairment—Fludarabine—lymphatic system cancer	0.00811	0.0091	CcSEcCtD
Olopatadine—Oedema—Teniposide—lymphatic system cancer	0.0068	0.00763	CcSEcCtD
Olopatadine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0068	0.00763	CcSEcCtD
Olopatadine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0068	0.00763	CcSEcCtD
Olopatadine—Infection—Teniposide—lymphatic system cancer	0.00676	0.00758	CcSEcCtD
Olopatadine—Malaise—Fludarabine—lymphatic system cancer	0.00661	0.00741	CcSEcCtD
Olopatadine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00653	0.00733	CcSEcCtD
Olopatadine—Cough—Fludarabine—lymphatic system cancer	0.00639	0.00717	CcSEcCtD
Olopatadine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00631	0.00709	CcSEcCtD
Olopatadine—Discomfort—Fludarabine—lymphatic system cancer	0.00616	0.00692	CcSEcCtD
Olopatadine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00614	0.00689	CcSEcCtD
Olopatadine—Dyspnoea—Teniposide—lymphatic system cancer	0.00607	0.00681	CcSEcCtD
Olopatadine—Depression—Carmustine—lymphatic system cancer	0.00598	0.00671	CcSEcCtD
Olopatadine—Oedema—Fludarabine—lymphatic system cancer	0.00598	0.00671	CcSEcCtD
Olopatadine—Infection—Fludarabine—lymphatic system cancer	0.00594	0.00667	CcSEcCtD
Olopatadine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00587	0.00658	CcSEcCtD
Olopatadine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00586	0.00658	CcSEcCtD
Olopatadine—Urinary tract infection—Carmustine—lymphatic system cancer	0.00583	0.00654	CcSEcCtD
Olopatadine—Rash—Mechlorethamine—lymphatic system cancer	0.00582	0.00653	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00581	0.00652	CcSEcCtD
Olopatadine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00581	0.00652	CcSEcCtD
Olopatadine—Depression—Vincristine—lymphatic system cancer	0.00571	0.00641	CcSEcCtD
Olopatadine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00569	0.00639	CcSEcCtD
Olopatadine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00561	0.00629	CcSEcCtD
Olopatadine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00556	0.00624	CcSEcCtD
Olopatadine—Nausea—Mechlorethamine—lymphatic system cancer	0.00548	0.00615	CcSEcCtD
Olopatadine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00542	0.00608	CcSEcCtD
Olopatadine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00542	0.00608	CcSEcCtD
Olopatadine—Abdominal pain—Teniposide—lymphatic system cancer	0.00538	0.00603	CcSEcCtD
Olopatadine—Body temperature increased—Teniposide—lymphatic system cancer	0.00538	0.00603	CcSEcCtD
Olopatadine—Erythema—Bleomycin—lymphatic system cancer	0.00537	0.00603	CcSEcCtD
Olopatadine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00536	0.00601	CcSEcCtD
Olopatadine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00533	0.00598	CcSEcCtD
Olopatadine—Ulcer—Methotrexate—lymphatic system cancer	0.00525	0.00589	CcSEcCtD
Olopatadine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00523	0.00587	CcSEcCtD
Olopatadine—Visual impairment—Carmustine—lymphatic system cancer	0.00519	0.00582	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00516	0.00579	CcSEcCtD
Olopatadine—Fatigue—Fludarabine—lymphatic system cancer	0.00516	0.00578	CcSEcCtD
Olopatadine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00512	0.00574	CcSEcCtD
Olopatadine—Pain—Fludarabine—lymphatic system cancer	0.00511	0.00574	CcSEcCtD
Olopatadine—Eye disorder—Carmustine—lymphatic system cancer	0.00503	0.00565	CcSEcCtD
Olopatadine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00502	0.00563	CcSEcCtD
Olopatadine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00501	0.00562	CcSEcCtD
Olopatadine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00498	0.00559	CcSEcCtD
Olopatadine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00497	0.00558	CcSEcCtD
Olopatadine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00493	0.00553	CcSEcCtD
Olopatadine—Asthenia—Teniposide—lymphatic system cancer	0.00488	0.00548	CcSEcCtD
Olopatadine—Malaise—Bleomycin—lymphatic system cancer	0.00484	0.00544	CcSEcCtD
Olopatadine—Pruritus—Teniposide—lymphatic system cancer	0.00481	0.0054	CcSEcCtD
Olopatadine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00473	0.0053	CcSEcCtD
Olopatadine—Erythema—Carmustine—lymphatic system cancer	0.00469	0.00526	CcSEcCtD
Olopatadine—Cough—Bleomycin—lymphatic system cancer	0.00469	0.00526	CcSEcCtD
Olopatadine—Diarrhoea—Teniposide—lymphatic system cancer	0.00465	0.00522	CcSEcCtD
Olopatadine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00463	0.0052	CcSEcCtD
Olopatadine—Back pain—Carmustine—lymphatic system cancer	0.00454	0.00509	CcSEcCtD
Olopatadine—Discomfort—Bleomycin—lymphatic system cancer	0.00452	0.00507	CcSEcCtD
Olopatadine—Vision blurred—Carmustine—lymphatic system cancer	0.00442	0.00496	CcSEcCtD
Olopatadine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00441	0.00494	CcSEcCtD
Olopatadine—Oedema—Bleomycin—lymphatic system cancer	0.00438	0.00492	CcSEcCtD
Olopatadine—Erythema—Mitoxantrone—lymphatic system cancer	0.00436	0.00489	CcSEcCtD
Olopatadine—Infection—Bleomycin—lymphatic system cancer	0.00436	0.00489	CcSEcCtD
Olopatadine—Back pain—Vincristine—lymphatic system cancer	0.00433	0.00486	CcSEcCtD
Olopatadine—Vomiting—Teniposide—lymphatic system cancer	0.00433	0.00485	CcSEcCtD
Olopatadine—Asthenia—Fludarabine—lymphatic system cancer	0.00429	0.00481	CcSEcCtD
Olopatadine—Rash—Teniposide—lymphatic system cancer	0.00429	0.00481	CcSEcCtD
Olopatadine—Dermatitis—Teniposide—lymphatic system cancer	0.00429	0.00481	CcSEcCtD
Olopatadine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00427	0.00479	CcSEcCtD
Olopatadine—Headache—Teniposide—lymphatic system cancer	0.00426	0.00478	CcSEcCtD
Olopatadine—Pruritus—Fludarabine—lymphatic system cancer	0.00423	0.00475	CcSEcCtD
Olopatadine—Back pain—Mitoxantrone—lymphatic system cancer	0.00422	0.00473	CcSEcCtD
Olopatadine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00411	0.00461	CcSEcCtD
Olopatadine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00409	0.00459	CcSEcCtD
Olopatadine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00404	0.00454	CcSEcCtD
Olopatadine—Nausea—Teniposide—lymphatic system cancer	0.00404	0.00453	CcSEcCtD
Olopatadine—Malaise—Mitoxantrone—lymphatic system cancer	0.00393	0.00441	CcSEcCtD
Olopatadine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00391	0.00439	CcSEcCtD
Olopatadine—Oedema—Carmustine—lymphatic system cancer	0.00383	0.00429	CcSEcCtD
Olopatadine—Visual disturbance—Methotrexate—lymphatic system cancer	0.00381	0.00427	CcSEcCtD
Olopatadine—Cough—Mitoxantrone—lymphatic system cancer	0.0038	0.00427	CcSEcCtD
Olopatadine—Infection—Carmustine—lymphatic system cancer	0.0038	0.00427	CcSEcCtD
Olopatadine—Vomiting—Fludarabine—lymphatic system cancer	0.0038	0.00427	CcSEcCtD
Olopatadine—Rash—Fludarabine—lymphatic system cancer	0.00377	0.00423	CcSEcCtD
Olopatadine—Dermatitis—Fludarabine—lymphatic system cancer	0.00377	0.00423	CcSEcCtD
Olopatadine—Pain—Bleomycin—lymphatic system cancer	0.00375	0.00421	CcSEcCtD
Olopatadine—Headache—Fludarabine—lymphatic system cancer	0.00375	0.0042	CcSEcCtD
Olopatadine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00367	0.00411	CcSEcCtD
Olopatadine—Oedema—Vincristine—lymphatic system cancer	0.00365	0.0041	CcSEcCtD
Olopatadine—Infection—Vincristine—lymphatic system cancer	0.00363	0.00407	CcSEcCtD
Olopatadine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00361	0.00405	CcSEcCtD
Olopatadine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00358	0.00402	CcSEcCtD
Olopatadine—Oedema—Mitoxantrone—lymphatic system cancer	0.00356	0.00399	CcSEcCtD
Olopatadine—Nausea—Fludarabine—lymphatic system cancer	0.00355	0.00399	CcSEcCtD
Olopatadine—Infection—Mitoxantrone—lymphatic system cancer	0.00353	0.00397	CcSEcCtD
Olopatadine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00347	0.00389	CcSEcCtD
Olopatadine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00346	0.00388	CcSEcCtD
Olopatadine—Dyspnoea—Carmustine—lymphatic system cancer	0.00341	0.00383	CcSEcCtD
Olopatadine—Somnolence—Carmustine—lymphatic system cancer	0.0034	0.00382	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0033	0.00371	CcSEcCtD
Olopatadine—Pain—Carmustine—lymphatic system cancer	0.00327	0.00367	CcSEcCtD
Olopatadine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00323	0.00362	CcSEcCtD
Olopatadine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00317	0.00356	CcSEcCtD
Olopatadine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00316	0.00355	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00315	0.00354	CcSEcCtD
Olopatadine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00315	0.00354	CcSEcCtD
Olopatadine—Fatigue—Vincristine—lymphatic system cancer	0.00315	0.00353	CcSEcCtD
Olopatadine—Asthenia—Bleomycin—lymphatic system cancer	0.00315	0.00353	CcSEcCtD
Olopatadine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00313	0.00351	CcSEcCtD
Olopatadine—Pain—Vincristine—lymphatic system cancer	0.00312	0.00351	CcSEcCtD
Olopatadine—Pruritus—Bleomycin—lymphatic system cancer	0.0031	0.00348	CcSEcCtD
Olopatadine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00307	0.00344	CcSEcCtD
Olopatadine—Pain—Mitoxantrone—lymphatic system cancer	0.00304	0.00341	CcSEcCtD
Olopatadine—Body temperature increased—Carmustine—lymphatic system cancer	0.00303	0.00339	CcSEcCtD
Olopatadine—Abdominal pain—Carmustine—lymphatic system cancer	0.00303	0.00339	CcSEcCtD
Olopatadine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00299	0.00335	CcSEcCtD
Olopatadine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00293	0.00329	CcSEcCtD
Olopatadine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00291	0.00326	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.0029	0.00325	CcSEcCtD
Olopatadine—Body temperature increased—Vincristine—lymphatic system cancer	0.00289	0.00324	CcSEcCtD
Olopatadine—Abdominal pain—Vincristine—lymphatic system cancer	0.00289	0.00324	CcSEcCtD
Olopatadine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00282	0.00316	CcSEcCtD
Olopatadine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00281	0.00316	CcSEcCtD
Olopatadine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00281	0.00316	CcSEcCtD
Olopatadine—Vomiting—Bleomycin—lymphatic system cancer	0.00279	0.00313	CcSEcCtD
Olopatadine—Infestation NOS—Methotrexate—lymphatic system cancer	0.00278	0.00312	CcSEcCtD
Olopatadine—Infestation—Methotrexate—lymphatic system cancer	0.00278	0.00312	CcSEcCtD
Olopatadine—Depression—Methotrexate—lymphatic system cancer	0.00277	0.00311	CcSEcCtD
Olopatadine—Rash—Bleomycin—lymphatic system cancer	0.00276	0.0031	CcSEcCtD
Olopatadine—Dermatitis—Bleomycin—lymphatic system cancer	0.00276	0.0031	CcSEcCtD
Olopatadine—Asthenia—Carmustine—lymphatic system cancer	0.00275	0.00308	CcSEcCtD
Olopatadine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.0027	0.00303	CcSEcCtD
Olopatadine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00269	0.00302	CcSEcCtD
Olopatadine—Epistaxis—Methotrexate—lymphatic system cancer	0.00262	0.00294	CcSEcCtD
Olopatadine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00262	0.00294	CcSEcCtD
Olopatadine—Asthenia—Vincristine—lymphatic system cancer	0.00262	0.00294	CcSEcCtD
Olopatadine—Diarrhoea—Carmustine—lymphatic system cancer	0.00262	0.00294	CcSEcCtD
Olopatadine—Nausea—Bleomycin—lymphatic system cancer	0.0026	0.00292	CcSEcCtD
Olopatadine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00255	0.00286	CcSEcCtD
Olopatadine—Dizziness—Carmustine—lymphatic system cancer	0.00253	0.00284	CcSEcCtD
Olopatadine—Diarrhoea—Vincristine—lymphatic system cancer	0.0025	0.0028	CcSEcCtD
Olopatadine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00248	0.00278	CcSEcCtD
Olopatadine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00243	0.00273	CcSEcCtD
Olopatadine—Vomiting—Carmustine—lymphatic system cancer	0.00243	0.00273	CcSEcCtD
Olopatadine—Dizziness—Vincristine—lymphatic system cancer	0.00242	0.00271	CcSEcCtD
Olopatadine—Rash—Carmustine—lymphatic system cancer	0.00241	0.00271	CcSEcCtD
Olopatadine—Dermatitis—Carmustine—lymphatic system cancer	0.00241	0.0027	CcSEcCtD
Olopatadine—Visual impairment—Methotrexate—lymphatic system cancer	0.0024	0.0027	CcSEcCtD
Olopatadine—Headache—Carmustine—lymphatic system cancer	0.0024	0.00269	CcSEcCtD
Olopatadine—Eye disorder—Methotrexate—lymphatic system cancer	0.00233	0.00262	CcSEcCtD
Olopatadine—Vomiting—Vincristine—lymphatic system cancer	0.00232	0.00261	CcSEcCtD
Olopatadine—Rash—Vincristine—lymphatic system cancer	0.0023	0.00258	CcSEcCtD
Olopatadine—Dermatitis—Vincristine—lymphatic system cancer	0.0023	0.00258	CcSEcCtD
Olopatadine—Headache—Vincristine—lymphatic system cancer	0.00229	0.00257	CcSEcCtD
Olopatadine—Nausea—Carmustine—lymphatic system cancer	0.00227	0.00255	CcSEcCtD
Olopatadine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00226	0.00254	CcSEcCtD
Olopatadine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00225	0.00253	CcSEcCtD
Olopatadine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00225	0.00252	CcSEcCtD
Olopatadine—Rash—Mitoxantrone—lymphatic system cancer	0.00224	0.00252	CcSEcCtD
Olopatadine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00224	0.00251	CcSEcCtD
Olopatadine—Headache—Mitoxantrone—lymphatic system cancer	0.00223	0.0025	CcSEcCtD
Olopatadine—Erythema—Methotrexate—lymphatic system cancer	0.00217	0.00244	CcSEcCtD
Olopatadine—Nausea—Vincristine—lymphatic system cancer	0.00217	0.00243	CcSEcCtD
Olopatadine—Dysgeusia—Methotrexate—lymphatic system cancer	0.00213	0.00239	CcSEcCtD
Olopatadine—Nausea—Mitoxantrone—lymphatic system cancer	0.00211	0.00237	CcSEcCtD
Olopatadine—Back pain—Methotrexate—lymphatic system cancer	0.0021	0.00236	CcSEcCtD
Olopatadine—Vision blurred—Methotrexate—lymphatic system cancer	0.00205	0.0023	CcSEcCtD
Olopatadine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00202	0.00226	CcSEcCtD
Olopatadine—Malaise—Methotrexate—lymphatic system cancer	0.00196	0.0022	CcSEcCtD
Olopatadine—Cough—Methotrexate—lymphatic system cancer	0.0019	0.00213	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00184	0.00206	CcSEcCtD
Olopatadine—Discomfort—Methotrexate—lymphatic system cancer	0.00183	0.00205	CcSEcCtD
Olopatadine—Infection—Methotrexate—lymphatic system cancer	0.00176	0.00198	CcSEcCtD
Olopatadine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00174	0.00195	CcSEcCtD
Olopatadine—Skin disorder—Methotrexate—lymphatic system cancer	0.00172	0.00193	CcSEcCtD
Olopatadine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00158	0.00177	CcSEcCtD
Olopatadine—Somnolence—Methotrexate—lymphatic system cancer	0.00158	0.00177	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00153	0.00172	CcSEcCtD
Olopatadine—Fatigue—Methotrexate—lymphatic system cancer	0.00153	0.00171	CcSEcCtD
Olopatadine—Pain—Methotrexate—lymphatic system cancer	0.00152	0.0017	CcSEcCtD
Olopatadine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00146	0.00164	CcSEcCtD
Olopatadine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00145	0.00163	CcSEcCtD
Olopatadine—Abdominal pain—Methotrexate—lymphatic system cancer	0.0014	0.00157	CcSEcCtD
Olopatadine—Body temperature increased—Methotrexate—lymphatic system cancer	0.0014	0.00157	CcSEcCtD
Olopatadine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00131	0.00147	CcSEcCtD
Olopatadine—Asthenia—Methotrexate—lymphatic system cancer	0.00127	0.00143	CcSEcCtD
Olopatadine—Pruritus—Methotrexate—lymphatic system cancer	0.00125	0.00141	CcSEcCtD
Olopatadine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00121	0.00136	CcSEcCtD
Olopatadine—Dizziness—Methotrexate—lymphatic system cancer	0.00117	0.00132	CcSEcCtD
Olopatadine—Vomiting—Methotrexate—lymphatic system cancer	0.00113	0.00126	CcSEcCtD
Olopatadine—Rash—Methotrexate—lymphatic system cancer	0.00112	0.00125	CcSEcCtD
Olopatadine—Dermatitis—Methotrexate—lymphatic system cancer	0.00112	0.00125	CcSEcCtD
Olopatadine—Headache—Methotrexate—lymphatic system cancer	0.00111	0.00125	CcSEcCtD
Olopatadine—Nausea—Methotrexate—lymphatic system cancer	0.00105	0.00118	CcSEcCtD
